Leadership

Per Lundin

Per Lundin is a serial entrepreneur who serves as Co-Founder & Chief Executive Officer of Evox Therapeutics Ltd. He has ~15 years’ experience founding, leading and advising biotech companies developing advanced therapies. Prior to co-founding and building out Evox, he founded and led IsletOne Therapeutics, a cell therapy company developing allogeneic cell therapies for autoimmune and inflammatory diseases, which was ultimately acquired in PE-led trade sale. Over the last two decades, Per has been involved in the formation of five biotech companies developing products based on technologies ranging from cell therapies and exosomes to peptide-based drugs and non-viral delivery systems. He currently serves as board director of Breakthrough T1D International and Breakthrough T1D UK, the leading non-profit funder of research to cure, treat and prevent type 1 diabetes. He is a qualified European Patent Attorney with extensive business development and licensing experience; Per earned his PhD from the Karolinska Institute, his Master of Science in Biotechnology Engineering from the Royal Institute of Technology, and his Master of Business Administration from Stockholm University School of Business.

Kerry Jaycock

Kerry is a strategic and commercially-focused leader with significant experience in business change and transformation. Motivated by a passion to drive the culture and ethos of a company, as Head of HR at Centrica Customer Services she enabled the organisation to effectively engage with both their employees and with key audiences. With the ability to influence and build strong relationships at all levels across organisations, oversee and project manage large-scale restructuring and organisational change, Kerry is motivated to deliver through values, employee engagement and communication.

Dave Carter

Dave is Head of Research at Evox Therapeutics. He has over 20 years’ experience working on pioneering, multidisciplinary applied research projects. Prior to joining Evox, he led an exciting research team that focused on extracellular vesicles as a Professor at Oxford Brookes University where he secured over £1m in grant funding and published more than 50 peer-reviewed articles. He was an active member of the International Society for Extracellular Vesicles and co-founder and first president of the UK Society for Extracellular Vesicles. His passion for exosomes brought him to Evox in 2021, where he has since supported the development of the DeliverEX platform and contributed to several pipeline projects in a matrix approach. Dave obtained his PhD from the University of Cambridge where he provided the first direct in vivo demonstration that enhancers and promoters physically interact to regulate gene expression. He also spent a year at the Sanger Centre, contributing important mapping data for the Human Genome Project.

Bob Higton

Bob is VP Finance & Operations Director at Evox Therapeutics. With over 16 years’ financial experience, including a decade in the UK biotech sector, Bob is an established finance leader. He has played a pivotal role at Evox since joining in 2018, driving finance to support the company’s strategy.

Before joining Evox, Bob worked at Circassia Pharmaceuticals plc (now NIOX Group plc) where he helped scale the company post-IPO, working on multiple successful acquisitions during his tenure.

As an expert finance director, Bob has nurtured a culture of excellence within his team, empowering colleagues to excel. His financial insights have guided Evox through the complexities of biotech finance, enabling decisions that foster innovation and maintain the company’s leading position.

Bob is an ACCA certified accountant and graduated from the Reed Business School in Accounting and Finance.